These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10585366)

  • 1. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4.
    Garcia-Barceló M; Chow LY; Kum Chiu HF; Wing YK; Shing Lee DT; Lam KL; Waye MM
    Clin Chem; 1999 Dec; 45(12):2273-4. PubMed ID: 10585366
    [No Abstract]   [Full Text] [Related]  

  • 2. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
    Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
    Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population.
    Xie HG
    Life Sci; 2000 Feb; 66(14):PL175-81. PubMed ID: 10755474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism.
    Goldstein JA; Blaisdell J
    Methods Enzymol; 1996; 272():210-8. PubMed ID: 8791779
    [No Abstract]   [Full Text] [Related]  

  • 6. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.
    Ibeanu GC; Blaisdell J; Ghanayem BI; Beyeler C; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Daly AK; Goldstein JA
    Pharmacogenetics; 1998 Apr; 8(2):129-35. PubMed ID: 10022751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
    Ferguson RJ; De Morais SM; Benhamou S; Bouchardy C; Blaisdell J; Ibeanu G; Wilkinson GR; Sarich TC; Wright JM; Dayer P; Goldstein JA
    J Pharmacol Exp Ther; 1998 Jan; 284(1):356-61. PubMed ID: 9435198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.
    Ibeanu GC; Goldstein JA; Meyer U; Benhamou S; Bouchardy C; Dayer P; Ghanayem BI; Blaisdell J
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1490-5. PubMed ID: 9732415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
    Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
    J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual and ethnic differences in CYP2C19 activity in Chinese populations.
    Shu Y; Zhou HH
    Acta Pharmacol Sin; 2000 Mar; 21(3):193-9. PubMed ID: 11324414
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.
    Xie HG; Kim RB; Stein CM; Wilkinson GR; Wood AJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):402-8. PubMed ID: 10510153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
    Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
    Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.
    de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH
    Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
    Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
    Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.
    Xie HG; Stein CM; Kim RB; Wilkinson GR; Flockhart DA; Wood AJ
    Pharmacogenetics; 1999 Oct; 9(5):539-49. PubMed ID: 10591534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
    Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
    Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.
    Ibeanu GC; Blaisdell J; Ferguson RJ; Ghanayem BI; Brosen K; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Goldstein JA
    J Pharmacol Exp Ther; 1999 Aug; 290(2):635-40. PubMed ID: 10411572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
    Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
    Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
    Brøsen K; de Morais SM; Meyer UA; Goldstein JA
    Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.